Skip to main content
SpringerLink
Log in

Adalimumab is an effective option in the treatment of patients with refractory rheumatoid arthritis

  • Drug and Profile
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs 2004; 18(2): 121–39

    Article  PubMed  CAS  Google Scholar 

  2. Keystone E, Kavanaugh AF, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract no. 468]. Arthritis Rheum 2002 Sep; 46(9 Suppl.): S205

    Google Scholar 

  3. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003 Jan; 48(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  4. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003 Dec; 30(12): 2563–71

    PubMed  CAS  Google Scholar 

  5. van de Putte LBA, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003 Dec; 62(12): 1168–77

    Article  PubMed  Google Scholar 

  6. van de Putte LBA, Atkins C, Malaise M, et al. Adalimumab (DE27) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract no. 467]. Arthritis Rheum 2002 Sep; 46(9 Suppl.): S205

    Google Scholar 

  7. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727–35

    Article  PubMed  CAS  Google Scholar 

  8. Furst DE, Weinblatt ME, Kavanaugh A, et al. Improvement of the individual ACR components in ACR20 responders in an adalimumab (HUMIRA) RA clinical trial [abstract no. 165]. Arthritis Rheum 2003 Sep; 48(9 Suppl.): S106

    Google Scholar 

  9. Weinblatt M, Keystone E, Furst D, et al. The Armada trial: efficacy and safety of adalimumab in patients with active RA at 24 months [abstract no. OP0107]. Ann Rheum Dis 2003 Jul; 62Suppl. 1: 98

    Google Scholar 

  10. Burmester GR, van de Putte LBA, Rau R, et al. Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refiactory RA [abstract]. Ann Rheum Dis 2003; 62Suppl. 1: 3

    Google Scholar 

  11. Wellborne F, Keystone EC, Kivitz, et al. Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, improved health-related quality of life in patients with active rheumatoid arthritis despite concomitant methotrexate therapy [abstract no. 1384]. Arthritis Rheum 2002 Sep; 46(9 Suppl.): S518

    Google Scholar 

  12. Schiff M, van de Putte LBA, Breedveld FC, et al. Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract no. THU0246]. Ann Rheum Dis 2003 Jul; 62Suppl. 1: 184

    Google Scholar 

  13. Abbott laboratories. Humira (adalimumab) prescribing information [online]. Available from URL: http://www.abbott.com [Accessed 2004 Nov 26]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adalimumab is an effective option in the treatment of patients with refractory rheumatoid arthritis. Drugs Ther. Perspect 21, 1–4 (2005). https://doi.org/10.2165/00042310-200521040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521040-00001

Search

Navigation